Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · GYRE THERAPEUTICS, INC. (GYRE)

Gyre Therapeutics signs new employment agreements with CEO Ying Luo and CFO Thomas Eastling

Neutral Impact 3 of 5 leadership Written later

Gyre Therapeutics entered into employment agreements on October 16, 2026 with CEO Ying Luo and CFO Thomas Eastling, under which both will continue in their current roles. The filing sets out their base salaries, bonus targets and severance terms, including enhanced payments if employment ends within three months before or twelve months after a change of control.

Key points

  • Dr. Ying Luo: annual base salary of $500,000 and a 2026 bonus target of $150,000
  • Thomas Eastling: annual base salary of $339,066 and a 2026 bonus target of $70,000
  • Change-of-control severance for both includes a lump sum of base salary plus target annual bonus and up to twelve months of COBRA premium reimbursement

The filing

CompanyGYRE THERAPEUTICS, INC. (GYRE)
Form8-K, current report
Filed with the SECOct 22, 2026, 4:01 PM ET
Accession number0001140361-26-040506

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:36 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 22, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.